Promoting Resiliency Among Lymphoma Survivors: The 3RP-Lymphoma



Status:Completed
Conditions:Lymphoma
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - 64
Updated:9/28/2018
Start Date:August 3, 2017
End Date:September 24, 2018

Use our guide to learn which trials are right for you!

The Relaxation Response Resiliency Program (3RP) was developed by researchers at the MGH
Benson-Henry Institute for Mind Body Medicine; This program has recently been adapted to
target the needs of individuals who have completed treatment for lymphoma (3RP-Lymphoma).

The Relaxation Response Resiliency Program, or 3RP, was developed by researchers at the MGH
Benson-Henry Institute for Mind Body Medicine. The 3RP is a group program that—through a
variety of mind-body approaches, such as imagery, relaxation, and yoga—seeks to buffer stress
and promote psychological resiliency and physical well-being.

The 3RP has not yet been carried out with individuals who have recently completed treatment
for lymphoma. As such, the investigators have adapted the standard 3RP program to target the
specific needs of lymphoma patients who are transitioning off active treatment. The
investigators are conducting this study to see if the adapted program, the 3RP-Lymphoma, is
effective at reducing stress and stress-related symptoms for people who have completed
treatment for lymphoma within the past two years. To develop the 3RP-Lymphoma, the
investigators conducted interviews with patients who had recently completed treatment to
learn about their experiences and their preferences for topics they would want to include in
a program tailored to their specific needs. The current phase of the feasibility study will
examine if the adapted program is feasible, acceptable, and helps promote stress management
among lymphoma survivors who are in the early stages of completing cancer treatment.

Inclusion Criteria:

- Aged 18-64

- Within 2 years post-treatment completion for lymphoma

- English speaking

- Able and willing to provide informed consent

- Cancer treatment or follow-up for lymphoma at the MGH Cancer Center

Exclusion Criteria:

- Unwilling or unable to participate in the study

- Unable to speak or read English

- Is medically, psychiatrically, or otherwise unable to participate (as determined by a
physician or study PI)

- Unwilling or unable to participate in group 3RP sessions delivered via the Partners
Telehealth videoconferencing software

- Participation in qualitative interview during Phase 1 (DF/HCC 16-396)
We found this trial at
1
site
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
Principal Investigator: Giselle K. Perez, PhD
Phone: 617-724-0765
?
mi
from
Boston, MA
Click here to add this to my saved trials